Login
CVRx, Inc. logo

CVRx, Inc.

barostim.com

What Do They Do?

Sells Barostim, an implantable device that sends electrical pulses to treat heart-failure symptoms, to hospitals serving patients with heart failure.

How Do They Make Money?

Hospitals buy Barostim devices, and customers pay after delivery.

FY2025 revenue

Who Are Their Customers?

Hospitals buy Barostim directly in the U.S. and Germany; in Austria, Spain and other European countries, sales go through distributors.

Do Revenues Turn Into Profits?

No. It lost $53.3M in FY2025.

Operating income, FY2025
−90% of revenue
▲ +14% (Loss) vs FY2024 (−$59.5M, −116%)
Net income, FY2025
−94% of revenue
▲ +11% (Loss) vs FY2024 (−$60M, −117%)
Free cash flow, FY2025
−72% of revenue
▼ −1% (Loss) vs FY2024 (−$40.5M, −79%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −6%
vs $14.7M in Q3 FY2025
Net income
▼ −10% (Loss)
vs −$12.9M in Q3 FY2025
  • Aug 6, 2026 CVRx issued full-year revenue guidance It expects full-year revenue of $58.0 million to $60.0 million and third-quarter revenue of $13.5 million to $14.5 million.
  • Jun 9, 2026 CFO Jared Oasheim announced plans to step down He will remain until a successor takes over and serve as an adviser through February 2027.

Growing. Revenue grew 4.3x in 4 years, from $13M in FY2021 to $56.7M in FY2025, about 44% a year.

Expanded product labeling The older report described seeking additional regulatory claims after the BeAT-HF study; the latest says the FDA expanded Barostim's labeling based on that study and describes a separate trial in a broader heart-failure group.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support